Navigation Links
Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX

- ViziLite Plus with TBlue630 -

PHOENIX, Sept. 4 /PRNewswire-FirstCall/ -- Zila, Inc.'s (Nasdaq: ZILA) ViziLite(R) Plus with Tblue630(TM) screening system for early detection of abnormalities which can lead to oral cancer, has been selected to identify pre-cancerous lesions in a Phase II study of Cetuximab (ERBITUX(R)), a leading cancer therapeutic for head and neck cancer developed by ImClone Systems (Nasdaq: IMCL) and distributed by Bristol-Meyers Squibb (NYSE: BMY).

The NIH has awarded a Specialized Program of Research Excellence (SPORE) grant for the study. The primary objective of the clinical trial is to evaluate ERBITUX efficacy in treating upper aerodigestive pre-cancer. ERBITUX is currently marketed for the treatment of head and neck cancer (including upper aerodigestive) as well as metastatic colorectal cancer.

Dr. Frank J.Bellizzi, President of Zila Pharmaceuticals, "We are pleased that Zila's ViziLite Plus with Tblue630 has been selected for use in this clinical trial. The use of ViziLite Plus in such an important study with the leading head and neck cancer therapeutic demonstrates its growing reputation as the premier oral cancer screening technology."

The coordinating center for the study is The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. The Protocol Chairman is Joseph Califano, M.D., of the Department of Otolaryngology-Head and Neck Surgery.

Over 30 clinical investigators at key academic research institutions and cancer research centers are scheduled to participate in the study. The Phase II study is anticipated to enroll and evaluate approximately 60 patients over a three-year period. Patients will be evaluated clinically and biopsies will be taken pre- and post-treatment. The biopsies will be analyzed histopathologically, but will also be analyzed for genetic changes using Zila's proprietary LOH assay. The assay is the only validated method for identifying biomarkers consistent with oral premalignencies and oral cancer.

About ViziLite(R) Plus

ViziLite(R) Plus is an oral screening technology that utilizes ViziLite, an advanced chemiluminescent light technology, with Tblue630. The Tblue630 marking system employs Zila Tolonium Chloride (ZTC(TM)), the only patented pharmaceutical-grade form of toluidine blue in an FDA-cleared device.

For more information about ViziLite Plus, visit

About Zila's LOH Assay

Biopsies are traditionally analyzed histopathologically to determine the histological changes in diseased tissue and enable classification of the tissue such as benign, dysplastic or cancerous. Leading cancer centers now recognize the value of also evaluating the DNA of biopsy samples for markers that signal that tissue is on the progression pathway to cancer. Zila has developed a proprietary DNA assay that evaluates chromosomal deletions by determining the loss of heterozygosity (LOH) of such biopsies. The validated LOH assay is utilized in the Zila OraTest Phase III clinical trial as well as the Erbitux Study, and the Company is evaluating commercial opportunities for the test.

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, is an oral cancer screening company focused on the prevention and treatment of oral disease. Zila is dedicated to establishing ViziLite(R) Plus as the new standard of care for the early detection of oral abnormalities that could lead to cancer, with an initial focus on the dental market through Pro-Dentec(R), a leading designer, manufacturer and marketer of Soft Tissue Management (STM(R)) products. Sold exclusively and directly to dental professionals, Pro-Dentec's core products include the Rota-dent(R) Professional Powered Brush, the Pro-Select3(R) Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM(R) products for both in-office and home-care use.

For more information about Zila, visit

SOURCE Zila, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
5. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. PromegaExpress Expands Easy Access to Products with New Cabinet
9. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
10. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
11. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
Post Your Comments:
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/28/2015)... , ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until ... most savings. , With possible savings of up to 20% off orders $80 or more ... of the website every few hours. , As a competitive e-commerce website for skin care ...
(Date:11/27/2015)... CO (PRWEB) , ... November 27, 2015 , ... According ... cities are not changing the way that they are handling security in light of ... police and security presence in an attempt to stop an attack from reaching U.S. ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women on ... organizations in the country. They have overseen financial turnarounds, shown commitment to their ... healthcare industry as a whole through their advocacy and professional efforts. , Becker's ...
Breaking Medicine News(10 mins):